Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
|Articles|July 1, 2007
- Applied Clinical Trials-07-01-2007
- Volume 0
- Issue 0
eShowcase: VISTA
Shorter Study Start-Up Times Targeted with Site Assessment Process Tool
Advertisement
Shorter Study Start-Up Times Targeted with Site Assessment Process Tool
Scientific Software Tools (Media, PA) has released the latest version of VISTA, its Web-based automated site technology assessment service. The new service incorporates additional features to assess for e-clinical studies.
VISTA allows qualitative surveys conducted by the investigative site-—including the technology survey—to be completed online, which eliminates paper-based surveys and manual entry into a database. Also, this Web-based process allows investigators a single point of contact for all required surveys.
VISTA presents the data obtained from the surveys and the technical assessment in XML format, which allows for easier data sharing into databases, as well as improved data sharing between different systems used by all parties involved, including clinical staff, investigators, sponsors, and others.
VISTA Plus includes additional data capture and reporting, and VISTA Services includes additional components to the basic service.
Scientific Software Tools, Inc., (610) 891-1640,
Articles in this issue
over 19 years ago
Reach Out to the Peopleover 19 years ago
A Survey of Survivorsover 19 years ago
Will the Real CRO Please Stand Upover 19 years ago
CRA: Jack of All Tradesover 19 years ago
Pediatric Policies Grow Upover 19 years ago
FDA Moves to Update Research Enterpriseover 19 years ago
Recruitment Done Rightover 19 years ago
eShowcase: iTrial EDCAdvertisement
Related to this article
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.
CRIO’s chief innovation officer, Mike Wenger touches on the two ways sites get AI adoption wrong.
CRIO’s Mike Wenger, speaker at this year's SCRS summit, maps how sites are actually deploying AI post-pilot stage.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, explains why the real advantage of faster data isn’t speed—it’s shortening the distance between signals, human judgment, and the next best action.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Syneos Health, Optum Partner on Adaptive Clinical Development Model
2
Where AI Governance in Clinical Development Falls Short
3
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
4
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
5